Lysosomes degrade dysfunctional intracellular components via three pathways: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Unlike the other two, CMA degrades cytosolic proteins with a recognized KFERQ-like motif in lysosomes and is important for cellular homeostasis. CMA activity declines with age and is altered in neurodegenerative diseases. Its impairment leads to the accumulation of aggregated proteins, some of which may be directly tied to the pathogenic processes of neurodegenerative diseases. Its induction may accelerate the clearance of pathogenic proteins and promote cell survival, representing a potential therapeutic approach for the treatment of neurodegenerative diseases. In this review, we summarize the current findings on how CMA is involved in neurodegenerative diseases, especially in Parkinson's disease.
Instead, proteins with the recognition motif KFERQ in their amino-acid sequences are targeted individually by this process [14] . Through this unique mechanism, CMA functions as an efficient system to selectively remove damaged or abnormal proteins. Since ~30% of cytosolic proteins are reported to contain the KFERQ motif, it is reasonable to believe that CMA has the potential to regulate many cellular processes [15, 16] .
Basic CMA Components
Chaperones Heat shock cognate 70 kDa protein (Hsc70) is a chaperone protein belonging to the heat shock protein 70 family [17, 18] . Cytosolic Hsc70 identifies a substrate protein via the KFERQ motif and transports it in complex to lysosomes for degradation [19] . Hsc70 in its ADP-bound form has a high affi nity for CMA substrates [20] and also helps the docking of unfolded substrate proteins on the lysosomal membrane [21] . Besides Hsc70, other co-chaperones including Hsc40 and Hsc90 can interact with Hsc70 and facilitate this process [18, 22] .
Receptor Lysosomal membrane glycoprotein (LAMP2A) functions as the receptor for CMA substrates [23] . Through its short cytosolic tail (GLKRHHTGYEQF), LAMP2A interacts directly with CMA substrate proteins and leads to their translocation into lysosomes [18] . The positively-charged residues located at the LAMP2A cytosolic tail are key to its interaction with substrates [24] . Overexpression of LAMP2A efficiently increases CMA activity, suggesting that its availability is rate-limiting for the entire process [18, 19, 25] .
Substrates The KFERQ motif is the classic amino-acid sequence that mediates the interaction of a substrate protein with Hsc70 [19, 26] . It includes a glutamine (Q) preceded or followed by a group of four amino-acids that contain a combination of acidic (D, E), basic (R, K), and bulky or hydrophobic (F, I, L, V) residues [27] . Such KFERQ motifs are found in ~30% of cytosolic proteins [28] . Some proteins such as the M2 isoform of pyruvate kinase have buried KFERQ motifs because of multimer formation. Other modifications such as ubiquitination can help dissociate the multimeric structure to expose the KFERQ motif, thus potentially regulating the spectrum of substrates [29] .
Machinery
CMA uses a mechanism that is quite distinct from the other two autophagy pathways [19] . At the cellular level, the CMA process consists of four steps. The fi rst includes substrate recognition and its targeting to the lysosomes. A typical CMA substrate protein with at least a KFERQ-like motif in its sequence is recognized and bound by Hsc70 [20] . The second step involves substrate binding to LAMP2A and unfolding [24] . The CMA substrate protein in complex with Hsc70 binds to the C-terminal cytosolic tail of LAMP2A
and this interaction quickly promotes the monomeric form of LAMP2A to assemble into a multimeric complex with a high molecular weight of ~700 KDa [24, 25] . The assembly of LAMP2A into this complex is dynamic and is in part initiated by the binding of the substrate to LAMP2A. The third step involves substrate translocation through the lysosomal membrane. It has been shown that both cytosolic and lysosome-associated Hsc70 participate in CMA translocation [13, [30] [31] [32] . Blockade of epitopes on lysosomeassociated Hsc70 can interfere with the internalization.
Thus, lysosome-associated Hsc70 plays an important role in substrate translocation after its delivery to the lysosomal surface by cytosolic Hsc70. The exact manner by which this translocation occurs has not yet been defined.
The membrane complex may function actively to pull a substrate protein into the lumen or hold onto it to prevent its return to the cytosol [15] . The stability of lysosome-associated Hsc70 in lysosomes is highly infl uenced by the pH of this organelle, an increase in the lysosomal pH leading to its degradation. The fourth step is substrate degradation in the lysosomal lumen. After the substrate is pulled into the lumen of the lysosome, LAMP2A dissociates rapidly from the translocation complex into monomers, a state that allows it to bind the next substrate [25] .
Regulation
CMA is influenced by multiple factors. For example, moderated levels of oxidative stress and neurotoxin treatment are known to increase the level of LAMP2A, the rate-limiting factor for CMA substrate flux, and enhance CMA activity [33] . Also, glial fibrillary acidic protein and elongation factor 1 alpha modulate CMA activity by regulating LAMP2A assembly/disassembly in a GTPdependent manner [34] . Moreover, CMA can be regulated through the ubiquitin-proteasome system. When this system is compromised, part of the protective cellular response involves enhancing CMA to prevent the buildup of toxic species [19, 35] . On the contrary, blockade of CMA often leads to the accumulation of poly-ubiquitinated proteins [36] .
In spite of these fi ndings, the critical mechanisms by which CMA machinery responds to signals and is modulated remain to be determined.
Role of CMA in Neurodegeneration
Neurodegenerative diseases are associated with risk factors such as aging, exposure to neurotoxins, and oxidative stress [37, 38] . Some of these factors also interact with the CMA process. CMA dysfunction may be involved in the pathogenic process of several neurodegenerative diseases, and some of the more recent advances supporting this link are summarized below.
Effects of Neurodegeneration-Associated Risk

Factors on CMA
Aging Aging is accompanied by a decline in the level of LAMP2A and CMA activity [39] . For example, in primary fibroblast cultures, CMA activity and lysosomal levels of LAMP2A are decreased in old-passage fibroblasts compared with early passages [40] . In the aged liver, although the transcription, synthesis, and lysosomal targeting of the LAMP2A protein appear to be the same in young and old rats, the stability of LAMP2A at the lysosomal membrane clearly decreases with aging [41] . The reason for this reduced stability is not clear, but it is possible that changes in the lipid microdomains of the lysosomal membrane contribute [41] .
Neurotoxins Several neurotoxins modulate CMA activity.
For example, 6-hyroxydopamine (6-OHDA) increases the levels of LAMP2A and Hsp90 in the nigral region in this rat model [42] . We showed that exposure to 6-OHDA increases the level of LAMP2A in a DA neuronal cell line and in the substantia nigra pars compacta (SNc) of mice and stimulates CMA activity [33] . Interestingly, toxins may alter the balance between CMA and substrate via mechanisms independent of a direct effect on lysosomes. Mitochondrial toxin also increases the levels of the CMA substrates α-synuclein and MEF2D [43] . But these changes seem to be due to changes in the regulation of their de novo synthesis but not their degradation by CMA. All of these fi ndings provide examples of neurotoxin-induced changes in CMA activity and a shift of the balance between CMA and its substrates, suggesting a role for CMA as a cellular protective response to alleviate toxin-induced damage [44] .
Oxidative stress Pro-oxidant compounds can cause changes in lysosomes isolated from cultured cells and rodent livers [45] . On the one hand, moderate oxidative stress seems to stimulate several key CMA components, including Hsp90, lysosomal Hsc70, and LAMP2A [33] . On the other hand, oxidative modifi cations of proteins may enhance their recognition by Hsc70. Together, these effects accelerate degradation via CMA, consistent with the evidence that antioxidants can partially prevent the CMA-mediated degradation of certain proteins following stress [46, 47] .
In support of this, oxidative modifications of the neuronal survival factor MEF2D have been reported to promote its removal by CMA [33] .
Role of CMA in PD
PD is one of the most common neurodegenerative diseases affecting the motor system. It results from the death of dopaminergic neurons in the SNc. Several gene mutations have been shown to cause familial PD [48] . Recent fi ndings indicate that inhibition of CMA is a common mechanism by which the mutated proteins encoded by some of these genes exert their toxic effects. α-synuclein and CMA PD is associated with an increase of α-synuclein protein [49] . α-synuclein contains a KFERQ-like motif and has been shown to be degraded by CMA [50] . Both monomers and dimers, but not oligomers, of α-synuclein are subjected to CMA regulation. Oxidation and nitration of α-synuclein may slightly hinder its degradation by CMA [51] . Furthermore, other post-translational modifi cations including phosphorylation and oligomerization may impair the turnover of α-synuclein, leading to its accumulation [52] .
I n t e r a c t i o n w i t h o x i d i z e d d o p a m i n e ( p r e s e n t i n dopaminergic neurons) may induce a conformational
change in the tertiary structure of α-synuclein, causing the protein to become misfolded and no longer internalizable by lysosomes. Pathogenic A30P and A53T α-synuclein mutants can bind to LAMP2A but are not internalized efficiently [8, 53] . Other mutant forms also hamper the CMA degradation pathway to varying degrees [54] . Therefore, all these conditions appear to impair CMA at the translocation and internalization step and may interfere with or inhibit the degradation of other CMA substrates.
Leucine-rich repeat kinase 2 (LRRK2) and CMA Mutation of the LRRK2 gene causes autosomal dominant PD. The LRRK2 protein is located in membrane microdomains, multivesicular bodies, and autophagic vesicles [55] , and it is also a substrate for CMA. However, the most common pathogenic mutant form of LRRK2, G2019S, is processed poorly through this pathway [56] . including α-synuclein [56] .
Mutant ubiquitin C-terminal hydrolase L1 (UCH-L1) and
CMA UCH-L1 is a de-ubiquitinating enzyme expressed abundantly in neurons. Its oxidative/carbonyl damage has been reported in sporadic PD and its mutation is associated with familial PD [57] . UCH-L1 interacts with LAMP2A, Hsc70, and Hsp90. At the cellular level, the UCH-L1 I93M mutant shows an enhanced interaction with the CMA components independent of the mono-ubiquitin-binding activity but remains stuck in the membrane, blocking the CMA machinery [58] . Expression of the UCH-L1 I93M mutant in cells results in an increase of α-synuclein and possibly other substrates secondary to CMA inhibition. Therefore, the aberrant interactions between the UCH-L1 mutant and CMA machinery may underlie the pathogenesis of PD caused by this mutated protein [58] .
Together, these fi ndings indicate that several proteins whose mutation is associated with familial PD focus their toxic activity on CMA, implying that inhibition of CMA is a key and a common mechanism in the pathogenic process of familial forms of PD caused by the mutation of multiple genes.
Neuronal survival factor myocyte enhancer factor 2D
(MEF2D) MEF2D, a transcription factor, plays an essential role in neuronal survival [59] [60] [61] . Our studies indicated that MEF2D is a CMA substrate [62] . Under normal conditions, non-functional MEF2D is transported to the cytoplasm and degraded by CMA and a decrease in CMA activity causes MEF2D accumulation in the cytoplasm. Both wild-type and A53T α-synuclein disrupt the CMA-mediated degradation of MEF2D and sensitize cells to stress [62, 63] . Consistent with this, cytoplasmic accumulation of MEF2D correlates positively with the level of α-synuclein in the brains of both α-synuclein transgenic mice and PD patients. Furthermore, our recent findings revealed that the neurotoxin 6-OHDA leads to oxidative modifi cation of MEF2D and inhibits its activity [33] .
Oxidatively-damaged MEF2D has a higher affinity for Alternations of CMA components The LAMP2 protein has three isoforms, LAMP2A, B, and C, which are affected differently in the early stages of PD [18] . The CMA receptor LAMP2A is selectively reduced related to the levels of α-synuclein. It has been reported that in PD brains, the levels of LAMP2A and Hsc70 are significantly reduced in the SNc and amygdala compared with those in agematched AD and control brain samples [11, 64] .
CMA in Other Neurodegenerative Diseases
Varying degrees of evidence indicate that dysfunctional CMA is also implicated in neurodegenerative diseases other than PD, including HD, AD, frontotemporal dementia, and amyotrophic lateral sclerosis.
In AD and tauopathies, CMA has been shown to infl uence the levels of neurofi brillary tangles resulting from the accumulation of mutant tau protein. The degradation of normal tau by CMA is mediated by its binding to Hsc70 via one of the two targeting motifs in its C-terminus [65] .
Interestingly, it appears that it is the fragments of mutant tau, but not the full-length protein itself, that translocate to the lysosomal membrane through Hsc70 recognition to undergo CMA-dependent cleavage by cathepsin L [65] .
Hsc70 and LAMP2A play roles in the degradation and clearance of Htt, whose gene mutation causes HD [52] . It has been reported that macroautophagic dysfunction triggers an increase in CMA in the early stage of HD, which may be a protective measure [12] . Moreover, phosphorylation of
Htt by inhibitor of kappa B kinase appears to promote its degradation in the lysosomes of unaffected neurons [66] .
Therefore, a decline in CMA activity may function as one of the aggravating factors in the progression of HD [10, 19] .
In frontotemporal dementia and amyotrophic lateral sclerosis, the pathogenic protein Tar-DNA binding protein 43 (TDP-43) forms cytosolic aggregates. TDP-43 is degraded by both ubiquitin proteasome and macroautophagy pathways, but there is also a report supporting the involvement of CMA in its degradation. This requires an interaction between Hsc70 and ubiquitinated TDP-43 [67] .
CMA as a Therapeutic Target in Treating Neurodegenerative Diseases
One of the most common characteristics among the different neurodegenerative diseases is the aggregation of deleterious proteins or inclusions in neurons [45, 68] , including
Htt protein in HD, amyloid-β in AD, and α-synuclein in PD. Many studies have established a strong link between a decline of CMA and the abnormal aggregation of such proteins in various models of neurodegenerative diseases [62, 69] , suggesting that CMA is a new and promising target for treating multiple neurodegenerative disorders.
Increased or restored CMA activity could be protective in several pathological conditions. As summarized above, the involvement of CMA in neurodegenerative diseases is complex. It is responsible for the clearance of aggregated or harmful proteins, and it is often the target of the toxic effects of these deleterious proteins. Rigorously designed studies are needed to thoroughly evaluate and determine whether enhancing CMA activity can provide substantial therapeutic benefi ts.
For the pharmacological manipulation of CMA activity, several molecules and their analogues have been reported to enhance autophagy with verified efficacy in several animal models of disease [68, 69] . Genetically, LAMP2A overexpression in mouse liver improves lysosomal as well as liver functions [45] . This suggests that reversing the aging-related impairment of CMA could have functional consequences. Similarly, studies on models of neurodegeneration also confirm the efficacy of targeting LAMP2A. Overexpression of LAMP2A in both cell lines and primary neurons efficiently increases the CMA activity and decreases the amount of α-synuclein [70] .
More remarkably, in the rat SNc, LAMP2A overexpression effectively reduces the levels of total α-synuclein and related aberrant inclusions, increases the survival of dopaminergic neurons, and alleviates the α-synucleininduced neurodegeneration [71, 72] . In addition, experimentally increasing CMA activity seems to provide therapeutic benefits in HD models [10] . Overall, these findings strongly suggest that manipulation of CMA activity may be an effective therapeutic strategy for treating neurodegenerative diseases.
Summary and Direction
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